212 related articles for article (PubMed ID: 26940692)
1. Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis.
Mei C; Chen N; Ding X; Yu X; Wang L; Qian J; Wang M; Jiang G; Li X; Hou F; Zuo L; Wang N; Liu H
Hemodial Int; 2016 Oct; 20(4):589-600. PubMed ID: 26940692
[TBL] [Abstract][Full Text] [Related]
2. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
5. Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akiba T; Akizawa T; Tsukamoto Y; Uchida E; Iwasaki M; Koshikawa S;
Ther Apher Dial; 2008 Apr; 12(2):117-25. PubMed ID: 18387159
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
Warady BA; Iles JN; Ariceta G; Dehmel B; Hidalgo G; Jiang X; Laskin B; Shahinfar S; Vande Walle J; Schaefer F
Pediatr Nephrol; 2019 Mar; 34(3):475-486. PubMed ID: 30506144
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
8. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
9. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
10. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
11. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
Fukagawa M; Shimazaki R; Akizawa T;
Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
Li D; Shao L; Zhou H; Jiang W; Zhang W; Xu Y
Endocrine; 2013 Feb; 43(1):68-77. PubMed ID: 22669774
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
[TBL] [Abstract][Full Text] [Related]
17. Use of cinacalcet for the management of hyperparathyroidism in patients with different degrees of renal failure.
Orellana JM; Esteban RJ; Castilla YA; Fernández-Castillo R; Nozal-Fernández G; Esteban MA; García-Valverde M; Bravo J
Nefrologia; 2016; 36(2):121-5. PubMed ID: 26906451
[TBL] [Abstract][Full Text] [Related]
18. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
[TBL] [Abstract][Full Text] [Related]
19. A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet.
Haq N; Chaaban A; Gebran N; Khan I; Abbachi F; Hassan M; Bernsen R; Abouchacra S
Int Urol Nephrol; 2014 Jan; 46(1):113-9. PubMed ID: 23529273
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials.
Xu J; Yang Y; Ma L; Fu P; Peng H
Int Urol Nephrol; 2019 Nov; 51(11):2027-2036. PubMed ID: 31531805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]